The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline

J Neurooncol. 2014 Jul;118(3):557-99. doi: 10.1007/s11060-013-1339-4. Epub 2014 Apr 17.


Question: What is the influence of targeted medical therapies on disease control and survival in the adult patient with progressive glioblastoma?

Targeted population: This recommendation applies to adult patients with progressive glioblastoma

Recommendations: Level III Treatment with bevacizumab is recommended as it provides improved disease control compared to historical controls as measured by best imaging response and progression free survival at 6 months. Given that there are a large number of therapies are available for progressive glioblastoma that may be applied under selected circumstances dependent on patient characteristics and treating physician judgment, it is strongly recommended that patients with progressive glioblastoma be enrolled in properly designed clinical investigations to provide convincing evidence of therapeutic value.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / metabolism
  • Disease Progression
  • Disease-Free Survival
  • Drug Delivery Systems / methods
  • Evidence-Based Medicine
  • Glioblastoma / drug therapy*
  • Glioblastoma / metabolism
  • Humans
  • Molecular Targeted Therapy*


  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Bevacizumab